Kirsty (insulin aspart-xjhz) is a rapid-acting insulin biosimilar that is interchangeable with novolog from a trusted name in insulin, biocon biologics. Aug 19, 2025kirsty for injection: Jul 15, 2025kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
Kirsty will be available as a single-patient-use. Jul 15, 2025the fda has approved kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions. Learn about kirsty (insulin aspart) usage and dosing.
Jul 16, 2025rapid-acting insulin kirsty: The fda has approved biocon biologics' insulin kirsty, an interchangeable biosimilar to novolog, enhancing diabetes management for patients with both adult. Jul 15, 2025kirsty is biosimiler to novolog.
Jul 16, 2025kirsty is a rapid-acting human insulin for improving glycaemic control in adults and paediatric patients with diabetes mellitus.
'/><text x='50%' y='52%' font-family='Arial,Helvetica,sans-serif' font-size='44' fill='white' text-anchor='middle' dominant-baseline='middle'>Bahlil</text></svg>)
